This combination medicine contains Voglibose 0.2mg, Glimepiride 2mg, and Metformin HCL 500mg, formulated to manage type 2 diabetes mellitus effectively. Voglibose is an alpha-glucosidase inhibitor that delays carbohydrate absorption, reducing post-meal blood sugar spikes. Glimepiride stimulates insulin secretion from the pancreas, helping lower fasting and postprandial glucose levels. Metformin improves insulin sensitivity and reduces hepatic glucose production, supporting overall glycemic control. This triple-action formula helps maintain stable blood sugar levels, improves HbA1c, and reduces long-term diabetes complications.
